Keymed Biosciences, Inc. (HK:2162) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Keymed Biosciences Inc. has shared positive results from a Phase I clinical study of their drug CMG901, a targeted treatment for advanced gastric cancer, at the ASCO Annual Meeting 2024. The study showed promising efficacy with a manageable safety profile for patients with Claudin 18.2-high G/GEJ cancer. Despite the encouraging data, the company cautions shareholders and potential investors that there’s no guarantee for the drug’s successful commercialization.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.